Research programme: PCSK9 protein inhibitors - Ionis

Drug Profile

Research programme: PCSK9 protein inhibitors - Ionis

Alternative Names: ISIS-394814; PCSK9 ASO; PCSK9 inhibitors; PCSK9 protein inhibitors - Bristol-Myers Squibb/Ionis; Proprotein convertase subtilisin kexin 9 inhibitors

Latest Information Update: 24 Dec 2015

Price : $50

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Bristol-Myers Squibb; Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 18 Dec 2015 Isis Pharmaceuticals is now called Ionis Pharmaceuticals
  • 31 Dec 2011 This research programme is no longer licensed to Bristol-Myers Squibb worldwide
  • 03 Feb 2011 A follow-on drug to BMS 844421 is in preclinical development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top